Ranbaxy

Ranbaxy Laboratories Limited was an Indian pharmaceutical company that was incorporated in India in 1961 and remained an entity until 2014. The company went public in 1973. Ownership of Ranbaxy changed twice over the course of its history.

In 2008, Japanese pharmaceutical company Daiichi Sankyo acquired a controlling share in Ranbaxy and in 2014, Sun Pharma acquired 100% of Ranbaxy in an all-stock deal. The Sun Pharma acquisition brought all new management to Ranbaxy, which had been laden with controversy (see Controversies below). Sun is the world’s fifth largest specialty generic pharmaceutical company.

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States.

Sun Pharma Laboratories Limited (“SPLL” or “Company”) is a pharmaceutical company having registered office in Mumbai, Maharashtra. The Company manufactures and markets pharmaceutical products in India. It was incorporated on January 17, 1997. On March 9, 2012, it became a wholly owned subsidiary of Sun Pharmaceutical Industries Limited (SPIL).

SPLL is engaged in the business of manufacturing and promoting Branded Generic pharmaceutical products and has a market share of 5.6% as per AIOCD AWACS ‐October 2015. The Company has four plants located in Sikkim and Jammu. It has a strong foothold in the therapeutic segments of Neurology & Psychiatry, Central Nervous System, Cardiology, Gastroenterology, Diabetes, Gynecology etc.

The Company is a market leader in India in the chronic segment, which contributes over 60% of its revenue as per AIOCD AWACS ‐October 2015. It offers a complete therapy basket with specialization in technically complex products. Among the country’s top 300 pharmaceutical brands, SPLL owns 19 brands. It has a strong field force of over 3,200 people who promote products to over 150,000 doctors across India. The field force has well-trained sales representatives with a strong track record of performance and enjoys one of the highest productivity amongst Indian pharmaceutical companies. The Company has consistently outperformed the average industry growth over years. As per February 2015 SMSRC report, the Company was ranked No.1 by prescriptions with 7 class of specialist doctors.